Table II.

Results of FTM as second-line therapy in malignant gliomas.

A, Objective responses, n (%)
	GBM	AG	Total patients
Response
Complete responses	0 (0)	0 (0)	0 (0)
Partial response	3 (9)	2 (33)	5 (13)
Stable disease	17 (50)	2 (33)	19 (47)
Progressive disease	14 (41)	2 (33)	16 (40)
Disease control	20 (59)	4 (67)	24 (60)
B, Survival data
Survival			Values
6 months-PFS, %			33
12 months-PFS, %			13
Median PFS, months (range)			4 (2–49) (3.02–5)
(95% CI)
6 months-OS, %			55
12 months-OS, %			30
Median OS, months (range)			9 (2.5–50.5) (7.36–10.64)
(95% CI)
Complete responses, %			33

GBM, glioblastoma multiforme; AG, anaplastic glioma; PFS, progression-free survival; OS, overall survival; CI, confidence interval.